Modeling adaptive drug resistance of colorectal cancer and therapeutic interventions with tumor spheroids

Investigating New Mechanisms of Acquired Resistance to Targeted Therapies: If You Hit Them Harder, Do They Get Up Differently?

(2020) Konstantinos V. Floros et al.   CANCER RESEARCH

Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms

(2020) Mark Borris D. Aldonza et al.   Science Advances

Organotypic breast tumor model elucidates dynamic remodeling of tumor microenvironment

(2020) Sunil Singh et al.   BIOMATERIALS

Human organoids: model systems for human biology and medicine

(2020) Jihoon Kim et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Establishment of patient-derived cancer organoids for drug-screening applications

(2020) Else Driehuis et al.   Nature Protocols

Targeting Tumor Microenvironment for Cancer Therapy

(2019) Catarina Roma-Rodrigues et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Quantitative Size-Based Analysis of Tumor Spheroids and Responses to Therapeutics

(2019) Pradip Shahi Thakuri et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer

(2019) Edoardo Isnaldi et al.   Journal of Translational Medicine

Hypoxia Induces Drug Resistance in Colorectal Cancer through the HIF-1α/miR-338-5p/IL-6 Feedback Loop

(2019) Ke Xu et al.   MOLECULAR THERAPY

MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer

(2019) Tianzuo Zhan et al.   Nature Communications

Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice

(2019) Tanmay M. Shekhar et al.   BMC CANCER

Role of hypoxia in cancer therapy by regulating the tumor microenvironment

(2019) Xinming Jing et al.   Molecular Cancer

A view on drug resistance in cancer

(2019) Neil Vasan et al.   NATURE

Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer

(2018) Suk Hyung Lee et al.   CELL

Targeting the tumour stroma to improve cancer therapy

(2018) Kenneth C. Valkenburg et al.   Nature Reviews Clinical Oncology

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

(2018) Georgios Vlachogiannis et al.   SCIENCE

A microfluidics platform for combinatorial drug screening on cancer biopsies

(2018) Federica Eduati et al.   Nature Communications

Cyclical Treatment of Colorectal Tumor Spheroids Induces Resistance to MEK Inhibitors

(2018) Pradip Shahi Thakuri et al.   Translational Oncology

Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing

(2017) Miguel Crespo et al.   NATURE MEDICINE

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

(2017) Zev A. Wainberg et al.   Targeted Oncology

Liquid-based three-dimensional tumor models for cancer research and drug discovery

(2016) Stephanie L Ham et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Characterization of Aqueous Two-Phase Systems from Volume and Density Measurements

(2016) Ehsan Atefi et al.   JOURNAL OF CHEMICAL AND ENGINEERING DATA

Multiparametric Analysis of Oncology Drug Screening with Aqueous Two-Phase Tumor Spheroids

(2016) Pradip Shahi Thakuri et al.   MOLECULAR PHARMACEUTICS

Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers

(2016) Giulia Bon et al.   Oncotarget

Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors

(2016) Stephanie L. Ham et al.   Advanced Healthcare Materials

Interfacial Tension Effect on Cell Partition in Aqueous Two-Phase Systems

(2015) Ehsan Atefi et al.   ACS Applied Materials & Interfaces

An analysis of the attrition of drug candidates from four major pharmaceutical companies

(2015) Michael J. Waring et al.   NATURE REVIEWS DRUG DISCOVERY

Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas

(2015) Jonathan J. Lee et al.   Clinical Epigenetics

High Throughput, Polymeric Aqueous Two-Phase Printing of Tumor Spheroids

(2014) Ehsan Atefi et al.   ADVANCED FUNCTIONAL MATERIALS

Colorectal cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

(2014) P. L. Bedard et al.   CLINICAL CANCER RESEARCH

Ultralow Interfacial Tensions of Aqueous Two-Phase Systems Measured Using Drop Shape

(2014) Ehsan Atefi et al.   LANGMUIR

Bone Marrow-Derived Mesenchymal Stromal Cells Promote Survival and Drug Resistance in Tumor Cells

(2014) S. A. Bergfeld et al.   MOLECULAR CANCER THERAPEUTICS

Drug resistance to targeted therapies: Déjà vu all over again

(2014) Floris H. Groenendijk et al.   Molecular Oncology

Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation

(2014) Jessie S. Jeon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Drug Resistance in Cancer: An Overview

(2014) Genevieve Housman et al.   Cancers

Automated, spatio-temporally controlled cell microprinting with polymeric aqueous biphasic system

(2013) David Petrak et al.   BIOTECHNOLOGY AND BIOENGINEERING

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

(2012) Jaafar Bennouna et al.   LANCET ONCOLOGY

Combinatorial drug therapy for cancer in the post-genomic era

(2012) Bissan Al-Lazikani et al.   NATURE BIOTECHNOLOGY

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

(2012) King Pan Ng et al.   NATURE MEDICINE

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation

(2011) H. Wang et al.   CANCER RESEARCH

A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

(2011) M. Hidalgo et al.   MOLECULAR CANCER THERAPEUTICS

Polymeric Aqueous Biphasic Systems for Non-Contact Cell Printing on Cells: Engineering Heterocellular Embryonic Stem Cell Niches

(2010) Hossein Tavana et al.   ADVANCED MATERIALS

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Biomaterials offer cancer research the third dimension

(2010) Dietmar W. Hutmacher   NATURE MATERIALS

BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

(2010) R. B. Corcoran et al.   Science Signaling

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

(2009) S. Wee et al.   CANCER RESEARCH

Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition

(2009) O. K. Mirzoeva et al.   CANCER RESEARCH

Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology

(2009) L. M. Ellis et al.   CLINICAL CANCER RESEARCH

The future of drug safety testing: expanding the view and narrowing the focus

(2009) James L. Stevens et al.   DRUG DISCOVERY TODAY

Nanolitre liquid patterning in aqueous environments for spatially defined reagent delivery to mammalian cells

(2009) H. Tavana et al.   NATURE MATERIALS